1. Home
  2. LWAY vs CBIO Comparison

LWAY vs CBIO Comparison

Compare LWAY & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LWAY

Lifeway Foods Inc.

HOLD

Current Price

$22.11

Market Cap

347.2M

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$8.89

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWAY
CBIO
Founded
1986
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
347.2M
389.7M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
LWAY
CBIO
Price
$22.11
$8.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$35.00
$27.17
AVG Volume (30 Days)
49.7K
228.1K
Earning Date
03-13-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$204,069,000.00
N/A
Revenue This Year
$15.23
N/A
Revenue Next Year
$13.72
N/A
P/E Ratio
$29.61
N/A
Revenue Growth
12.14
N/A
52 Week Low
$19.50
$8.72
52 Week High
$34.20
$21.40

Technical Indicators

Market Signals
Indicator
LWAY
CBIO
Relative Strength Index (RSI) 46.87 30.09
Support Level $21.25 $8.99
Resistance Level $22.50 $9.69
Average True Range (ATR) 0.64 0.81
MACD 0.06 -0.10
Stochastic Oscillator 40.61 9.25

Price Performance

Historical Comparison
LWAY
CBIO

About LWAY Lifeway Foods Inc.

Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: